ArticleViruses2016
Antiviral Screening of Multiple Compounds against Ebola Virus.
Article in Viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Ouabain exerts protective effects on SH-SY5Y cells upon Zika virus infection.Virology journal · 2026Article
- Improving Geldanamycin Production inMicroorganisms · 2025Article
- Cardiac glycosides: Looking beyond heart failure and atrial fibrillation.Indian journal of pharmacology · 2025Article
- Cardiac glycosides inhibit early and late vaccinia virus protein expression.The Journal of general virology · 2024Article
- Dual functional therapeutics: mitigating bacterial infection and associated inflammation.RSC medicinal chemistry · 2023Review
- Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection.Antimicrobial agents and chemotherapy · 2023Article
- Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development.Frontiers in pharmacology · 2022Review
- Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- Defending Antiviral Cationic Amphiphilic Drugs That May Cause Drug-Induced Phospholipidosis.Journal of chemical information and modeling · 2021Article
- Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses.Molecules (Basel, Switzerland) · 2021Review
- Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo.Microorganisms · 2021Article
- Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.bioRxiv : the preprint server for biology · 2021Article
- Natural Products Database Screening for the Discovery of Naturally Occurring SARS-Cov-2 Spike Glycoprotein Blockers.ChemistrySelect · 2020Article
- Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease.Antiviral research · 2020Article
- Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.Antiviral research · 2020Article
- Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions.Molecules (Basel, Switzerland) · 2020Review
- Elucidation of the mechanism of anti-herpes action of two novel semisynthetic cardenolide derivatives.Archives of virology · 2020Article
- Alphavirus Replication: The Role of Cardiac Glycosides and Ion Concentration in Host Cells.BioMed research international · 2020Review
- Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool.Expert review of anti-infective therapy · 2019Article
- Viroporins in the Influenza Virus.Cells · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures. A range of compounds currently available with broad antimicrobial activity have been tested for activity against EBOV. Using live EBOV, eighteen candidate compounds were screened for antiviral activity in vitro. The compounds were selected on a rational basis because their mechanisms of action suggested that they had the potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some antiviral activity against EBOV in previous tests. Nine compounds caused no reduction in viral replication despite cells remaining healthy, so they were excluded from further analysis (zidovudine; didanosine; stavudine; abacavir sulphate; entecavir; JB1a; Aimspro; celgosivir; and castanospermine). A second screen of the remaining compounds and the feasibility of appropriateness for in vivo testing removed six further compounds (ouabain; omeprazole; esomeprazole; Gleevec; D-LANA-14; and Tasigna). The three most promising compounds (17-DMAG; BGB324; and NCK-8) were further screened for in vivo activity in the guinea pig model of EBOV disease. Two of the compounds, BGB324 and NCK-8, showed some effect against lethal infection in vivo at the concentrations tested, which warrants further investigation. Further, these data add to the body of knowledge on the antiviral activities of multiple compounds against EBOV and indicate that the scientific community should invest more effort into the development of novel and specific antiviral compounds to treat Ebola virus disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.